Spontaneous Regression of Renal Cell Carcinoma and the Role of Prognostic Factors

2008 ◽  
pp. 355-366
Author(s):  
Tim Oliver ◽  
Tom Powles ◽  
Vinod Nargund ◽  
Dan Berney
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Spontaneous Regression

Prognostic factors in patients with pancreatic metastases from renal cell carcinoma (PM-RCC): Room for thinking about the role of surgery?

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e15563-e15563
Author(s):  
Matteo Santoni ◽  
Alessandro Conti ◽  
Camillo Porta ◽  
Linda Cerbone ◽  
Giuseppe Procopio ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Pancreatic Metastases

scholarly journals Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)

2021 ◽  
Vol 11 ◽  
Author(s):  
Marco Maruzzo ◽  
Elena Verzoni ◽  
Maria Giuseppa Vitale ◽  
Michele Dionese ◽  
Sebastiano Buti ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factors ◽  
Thyroid Hormone ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Free Survival ◽  
Line Setting

BackgroundThyroid hormone impairment, represented as an alteration in levels of thyroid hormones and a lower fT3/fT4 ratio, has been correlated with a worse prognosis for both cancer and non-cancer patients. The role of baseline thyroid function in patients with metastatic renal cell carcinoma (mRCC) however, has not been studied yet.Materials and MethodsWe recorded clinical data, baseline biochemical results, and oncological outcomes from 10 Oncology Units in Italy. We stratified patients into three groups according to the fT3/fT4 ratio value and subsequently analyzed differences in progression-free survival (PFS) and overall survival (OS) in the three groups. We also performed univariate and multivariate analyses to find prognostic factors for PFS and OS.ResultsWe analyzed 134 patients treated with systemic treatment for mRCC. Median PFS in the low, intermediate, and high fT3/fT4 ratio group were 7.5, 12.1, and 21.7 months respectively (p<0.001); median OS in the three groups were 36.5, 48.6, and 70.5 months respectively (p =0.006). The low fT3/fT4 ratio maintained its prognostic role at the multivariate analysis independently from IMDC and other well-established prognostic factors. The development of iatrogenic hypothyroidism was not associated with a better outcome.ConclusionWe found that baseline thyroid hormone impairment, represented by a low fT3/fT4 ratio, is a strong prognostic factor in patients treated for mRCC in first line setting and is independent of other parameters currently used in clinical practice.

Prognostic factors in renal cell carcinoma: Effect on prognosis of neoadjuvant and adjuvant treatments

1997 ◽  
Vol 64 (2) ◽  
pp. 217-223
Author(s):  
G. Castagnetti ◽  
G. Ferrari ◽  
A. Dotti ◽  
P. Ferrari
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factors ◽  
Side Effects ◽  
Partial Response ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Spontaneous Regression ◽  
Complete Response ◽  
New Drugs

– Medical treatment of metastatic renal cell carcinoma has undergone many changes since the eighties when therapeutical interest shifted to immunotherapy, due to description of spontaneous regression of pulmonary metastasis after nephrectomy and the fact that the illness was refractory to chemotherapy and radiotherapy. First reports of complete response and partial response (about 20%) obtained by interferon led to research resulting in the discovery and use of new drugs (interleukine) and immunocompetent cells (LAK and TIL cells) capable of increasing the percentage of response, but with very serious side effects (IL-2 i.v.). The association of interferon-interleukine administered subcutaneously is the most common and most effective therapy. The association between these drugs (IFN, IL-2) and immunocompentent cells (LAK and TIL cells) will have to be assessed in the future because, even if the first experiences are favourable, follow-up periods and patient numbers are still too small.

The Role of Radiotherapy for Adult Renal Cell Carcinoma

1992 ◽  
Vol 59 (6) ◽  
pp. 71-74
Author(s):  
S. Dal Fior ◽  
A. Bordin ◽  
T. Iannone
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Metastatic Disease ◽  
Local Control ◽  
Renal Cell ◽  
Survival Rates ◽  
Long Survival ◽  
Radiotherapy Techniques

In this paper the most important articles about the role of radiotherapy for renal cell carcinoma (CPR) are reviewed. Both pre- and post-operative radiotherapy do not seem to improve the survival rates, nor perhaps the local control in comparison with surgery. But trials have been limited and with evident bias: patients were staged without stratification for prognostic factors (grading and lymphonode metastases in particular) and radiotherapy techniques were often incorrect because of too frequent early and late damage. The role of radiotherapy for treating the metastatic disease is undisputed Particularly for patients with a single metastasis, because of the possibility of long survival if adequately controlled.

TRIM44 promotes cell proliferation and migration by inhibiting FRK in renal cell carcinoma

2020 ◽  
Author(s):  
Lungwani Muungo
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Proliferation ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Lymphatic Invasion ◽  
Cancer Specific Survival ◽  
Candidate Target ◽  
Candidate Target Gene ◽  
And Migration

TRIM44 has oncogenic roles in various cancers. However, TRIM44 expression andits function in renal cell carcinoma (RCC) are still unknown. Here in this study, weinvestigated the clinical significance of TRIM44 and its biological function in RCC.TRIM44 overexpression was significantly associated with clinical M stage, histologictype (clear cell) and presence of lymphatic invasion (P = .047, P = .005, and P = .028,respectively). Moreover, TRIM44 overexpression was significantly associated withpoor prognosis in terms of cancer-specific survival (P = .019). Gain-of-function andloss-of-function studies using TRIM44 and siTRIM44 transfection showed thatTRIM44 promotes cell proliferation and cell migration in two RCC cell lines, Caki1and 769P. To further investigate the role of TRIM44 in RCC, we performed integratedmicroarray analysis in Caki1 and 769P cells and explored the data in the Oncominedatabase. Interestingly, FRK was identified as a promising candidate target gene ofTRIM44, which was downregulated in RCC compared with normal renal tissues. Wefound that cell proliferation was inhibited by TRIM44 knockdown and then recoveredby siFRK treatment. Taken together, the present study revealed the associationbetween high expression of TRIM44 and poor prognosis in

Beyond Promoter: The Role of Macrophage in Invasion and Progression of Renal Cell Carcinoma

2020 ◽  
Vol 15 (7) ◽  
pp. 588-596
Author(s):  
Haibao Zhang ◽  
Guodong Zhu
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Microenvironment ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Cell Formation ◽  
Biological Behavior ◽  
Tumor Stem Cell ◽  
The Past ◽  
The Common

Renal cell carcinoma (RCC) is one of the common urologic neoplasms, and its incidence has been increasing over the past several decades; however, its pathogenesis is still unknown up to now. Recent studies have found that in addition to tumor cells, other cells in the tumor microenvironment also affect the biological behavior of the tumor. Among them, macrophages exist in a large amount in tumor microenvironment, and they are generally considered to play a key role in promoting tumorigenesis. Therefore, we summarized the recent researches on macrophage in the invasiveness and progression of RCC in latest years, and we also introduced and discussed many studies about macrophage in RCC to promote angiogenesis by changing tumor microenvironment and inhibit immune response in order to activate tumor progression. Moreover, macrophage interactes with various cytokines to promote tumor proliferation, invasion and metastasis, and it also promotes tumor stem cell formation and induces drug resistance in the progression of RCC. The highlight of this review is to make a summary of the roles of macrophage in the invasion and progression of RCC; at the same time to raise some potential and possible targets for future RCC therapy.

Sign in / Sign up

Export Citation Format

Share Document